Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Trial
Completed
Qilu Pharmaceutical Co., Ltd.
Phase 3
2019-10-18
QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein for injection,
is a romiplostim (Nplate®) biosimilar for the treatment of primary immune thrombocytopenia
(ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adults'
patients with primary chronic ITP during a 24-week treatment period.
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Completed
Amgen
Phase 1/Phase 2
2002-12-02
The purpose of this study is to assess the safety and tolerability of AMG 531 (romiplostim),
a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in adults
with immune thrombocytopenic purpura.
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
Terminated
University of Southern California
Phase 2
2010-06-30
RATIONALE: Romiplostim may cause the body to make platelets.
PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating
hepatitis C-infected patients with thrombocytopenia.
Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
Unknown status
Amgen
Phase 2
2011-11-01
This is a monocentric, prospective phase II trial addressing safety and capability to prevent
grade-4 Chemotherapy-induced Thrombocytopenia (CIT) of romiplostim in patients with NHL.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
